Iovance Biotherapeutics (IOVA) Corporate presentation summary

Leadership and market position

• Recognized as a global leader in innovating, developing, and delivering tumor-infiltrating lymphocyte (TIL) therapy for cancer patients, with two approved products: Amtagvi (lifileucel) and Proleukin (aldesleukin).

• Over 1,500 patients have been treated with commercial and clinical TIL products, and more than 85 treatment centers were operational as of year-end 2025.

• Maintains global portfolio and technology platform rights, with ongoing regulatory reviews in the UK, Australia, Switzerland, and the EU.

Financial performance and outlook

• Achieved $264M in full-year 2025 revenue, meeting guidance of $250M–$300M.

• Ended 2025 with $303M in cash, providing a runway into Q3 2027.

• Reported 30% quarterly revenue growth in Q4 2025 and a 50% gross margin.

• Strategic restructuring and cost control initiatives are expected to further improve margins.

Product highlights and clinical data

• Amtagvi is the first and only FDA-approved one-time, individualized T cell therapy for solid tumor cancer, specifically for 2L+ advanced melanoma.

• Demonstrated 31.4% objective response rate (ORR) and 36.5 months median duration of response (mDOR) at five-year follow-up in advanced melanoma.

• Real-world data show a 44% ORR and 73% disease control rate (DCR), with higher response rates in patients with fewer prior therapies.

• Broad payer coverage with over 250 million patient lives covered and typical financial clearance in about three weeks.